Roger P. A’hern
#154,341
Most Influential Person Now
Roger P. A’hern's AcademicInfluence.com Rankings
Roger P. A’hernphilosophy Degrees
Philosophy
#8672
World Rank
#12095
Historical Rank
Logic
#5700
World Rank
#7121
Historical Rank
Roger P. A’hernbiology Degrees
Biology
#11780
World Rank
#15203
Historical Rank
Genetics
#1283
World Rank
#1385
Historical Rank
Molecular Biology
#1853
World Rank
#1882
Historical Rank
Biochemistry
#1965
World Rank
#2106
Historical Rank
Download Badge
Philosophy Biology
Roger P. A’hern's Degrees
- PhD Molecular Biology Stanford University
- Doctorate Medicine Harvard University
Why Is Roger P. A’hern Influential?
(Suggest an Edit or Addition)Roger P. A’hern's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. (2015) (1670)
- Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011) (1439)
- Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial (2011) (1385)
- Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. (2010) (931)
- Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. (2009) (585)
- Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. (2007) (579)
- Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. (2009) (562)
- Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics (2008) (544)
- Excision margins in high-risk malignant melanoma. (2004) (433)
- Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review (2005) (388)
- Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). (1997) (371)
- Breast cancer molecular profiling with single sample predictors: a retrospective analysis. (2010) (362)
- Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea‐predominant irritable bowel syndrome (2009) (361)
- Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. (2000) (348)
- Sample size tables for exact single‐stage phase II designs (2001) (329)
- Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer (1990) (327)
- Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. (1999) (317)
- A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. (2000) (309)
- Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. (2004) (300)
- Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. (2006) (279)
- Fatigue in advanced cancer: a prospective controlled cross-sectional study (1999) (264)
- The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer (2009) (254)
- Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. (2009) (254)
- The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity. (1994) (246)
- Psychological effects of being offered choice of surgery for breast cancer (1994) (219)
- Non-pharmacological intervention for breathlessness in lung cancer (1996) (214)
- Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. (2001) (213)
- The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival (1990) (204)
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials (2019) (197)
- Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. (1993) (197)
- Surveillance following orchidectomy for stage I testicular seminoma. (1992) (196)
- Fatigue in patients with prostate cancer receiving hormone therapy. (2000) (190)
- Pineal and CNS germ cell tumors: Royal Marsden Hospital experience 1962-1987. (1990) (189)
- Are we using appropriate self-report questionnaires for detecting anxiety and depression in women with early breast cancer? (1999) (189)
- Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer. (1989) (186)
- Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. (1996) (181)
- Head and neck sarcomas: prognostic factors and implications for treatment. (1993) (180)
- A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. (2000) (174)
- The influence of radiotherapy on capsule formation and aesthetic outcome after immediate breast reconstruction using biodimensional anatomical expander implants. (2006) (171)
- Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). (2009) (164)
- Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. (2008) (156)
- Pelvic nerve plexus trauma at radical hysterectomy and simple hysterectomy (2000) (154)
- Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal selection (2012) (154)
- Impact of doxorubicin on survival in advanced ovarian cancer. (1995) (152)
- Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. (2010) (151)
- Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer (2010) (146)
- Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. (2002) (144)
- Hormone replacement therapy and survival after surgery for ovarian cancer. (1991) (140)
- Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers (2012) (137)
- Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. (1998) (136)
- Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement (2011) (136)
- Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer (1997) (135)
- Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. (2015) (135)
- Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. (2001) (129)
- An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non‐familial breast cancers (1998) (129)
- Thyroid cancer in children: the Royal Marsden Hospital experience. (2000) (127)
- Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer (2009) (121)
- Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance (2013) (116)
- Influence of cholecystectomy on symptoms (1991) (113)
- Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy (1998) (113)
- Natural history of stage IV epithelial ovarian cancer. (1999) (112)
- The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. (2004) (110)
- The impact of introducing intensity modulated radiotherapy into routine clinical practice. (2005) (109)
- Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. (2012) (108)
- Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. (2002) (105)
- Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. (1993) (104)
- Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. (1994) (102)
- Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone. (1990) (101)
- Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer (2006) (100)
- Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. (2010) (100)
- Intratumoral Estrogen Disposition in Breast Cancer (2010) (99)
- Treatment of nondysgerminomatous ovarian germ cell tumors (1999) (98)
- Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials? (2016) (97)
- Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. (2000) (97)
- The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK (1998) (96)
- Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. (1998) (96)
- Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast (2014) (96)
- Immediate Breast Reconstruction Using Biodimensional Anatomical Permanent Expander Implants: A Prospective Analysis of Outcome and Patient Satisfaction (2003) (95)
- Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer (2006) (95)
- Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. (2002) (93)
- Aggressive fibromatosis of the abdominal wall, limbs and limb girdles (2004) (92)
- Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. (1998) (91)
- Long‐term results in elderly patients with differentiated thyroid carcinoma (2003) (87)
- Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. (1991) (86)
- Prognosis of Lymph Node Metastasis in Soft Tissue Sarcoma (2004) (84)
- Does chemotherapy improve survival in advanced breast cancer? A statistical overview. (1988) (84)
- Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. (1991) (82)
- Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. (2011) (77)
- A question of choice: results of a prospective 3-year follow-up study of women with breast cancer (1994) (75)
- Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. (1995) (73)
- Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. (1998) (73)
- Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89? (1992) (73)
- Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. (2005) (72)
- Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer (2003) (71)
- Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction (1998) (70)
- Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. (1997) (69)
- Prediction of survival in a hospital-based continuing care unit. (1994) (68)
- Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. (2012) (68)
- ζ‐Chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia (2005) (67)
- Pelvic Nerve Plexus Trauma at Radical and Simple Hysterectomy: A Quantitative Study of Nerve Types in the Uterine Supporting Ligaments (2002) (67)
- A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma (2004) (66)
- Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer (2012) (66)
- Surgical excision of isolated renal‐bed recurrence after radical nephrectomy for renal cell carcinoma (2005) (66)
- A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers (2012) (65)
- A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. (2004) (64)
- Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. (2015) (64)
- The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. (2001) (63)
- Comparative validation of the SP6 antibody to Ki67 in breast cancer (2010) (62)
- Chemotherapy for ovarian cancer--a consensus statement on standard practice. (1998) (61)
- Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. (2011) (61)
- Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma (2004) (61)
- Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial. (2015) (61)
- First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537). (2009) (60)
- Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma (2004) (59)
- Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. (2004) (56)
- The significance of paracardiac lymph node enlargement in ovarian cancer. (1997) (56)
- Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century. (2003) (55)
- Was Young's syndrome caused by exposure to mercury in childhood? (1993) (55)
- Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. (2005) (54)
- Treatment accuracy of fractionated stereotactic radiotherapy. (2005) (54)
- Modified Staging System for Extremity Soft Tissue Sarcomas (1999) (53)
- A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. (2007) (53)
- New insights into p53 protein stabilisation in oral squamous cell carcinoma. (1999) (52)
- The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer (1999) (52)
- Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer (2003) (51)
- The activity of single-agent carboplatin in advanced seminoma. (1992) (51)
- Primary medical therapy for operable breast cancer. (1989) (50)
- Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study. (2009) (50)
- A quality-of-life study in high-risk (thickness > = or 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. (2004) (49)
- Effects of tamoxifen on uterus (1994) (49)
- The role of genetic factors in predisposition to squamous cell cancer of the head and neck (1999) (49)
- Modification of pain on injection of propofol—a comparison between lignocaine and procaine (1991) (48)
- Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group. (1996) (48)
- The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity (1995) (48)
- CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. (2004) (47)
- Gestational trophoblastic disease with liver metastases: the Charing Cross experience (1997) (47)
- A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. (2001) (46)
- Time‐related effects of estrogen withdrawal on proliferation‐ and cell death‐related events in MCF‐7 xenografts (1999) (46)
- Computed tomography in the assessment of response to limb compression in unilateral lymphoedema. (1995) (46)
- A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma (2015) (46)
- Correlation of in vitro lymphocyte radiosensitivity and gene expression with late normal tissue reactions following curative radiotherapy for breast cancer. (2012) (46)
- Experience in the use of the palliative care outcome scale (2005) (45)
- ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer (2009) (45)
- The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography? (2001) (43)
- When Breast Cancer Recurs: A 3‐Year Prospective Study of Psychological Morbidity (1996) (43)
- Pelvic nerve plexus trauma at radical and simple hysterectomy: A quantitative study of nerve types in the uterine supporting ligaments. (2002) (43)
- Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer (2010) (42)
- Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers. (2012) (42)
- First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537; CRUK/03/005). (2009) (41)
- Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. (1995) (41)
- The role of percutaneous nephrostomy in malignant urinary tract obstruction. (1993) (41)
- Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). (2005) (40)
- Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene (2000) (40)
- Prognostic Index for Extremity Soft Tissue Sarcomas With Isolated Local Recurrence (2001) (40)
- A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. (1994) (39)
- Influence of local recurrence on survival: A controversy reviewed from the perspective of soft tissue sarcoma (1991) (39)
- Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. (2013) (38)
- questionnaires and semistructured interviews mastectomy : prospective study using The psychosocial impact of bilateral prophylactic (2001) (38)
- Management of non-Hodgkin's lymphoma of the thyroid: the Royal Marsden Hospital experience. (2005) (37)
- Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. (2014) (37)
- Taxane benefit in breast cancer—a role for grade and chromosomal stability (2013) (37)
- Significance of tumour calcification in ovarian carcinoma. (2009) (36)
- Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. (2011) (36)
- Long-Term Quality-of-Life Assessment following One-Stage Immediate Breast Reconstruction Using Biodimensional Expander Implants: The Patient's Perspective (2008) (36)
- Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients (2012) (36)
- Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study (2010) (36)
- Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer (2013) (36)
- Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations (2013) (35)
- The use of the Rotterdam Symptom Checklist in palliative care. (1999) (35)
- Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials). (2015) (35)
- Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). (1995) (35)
- Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. (2009) (34)
- An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer (2005) (33)
- The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. (1997) (33)
- Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. (2006) (33)
- Outcome of malignant spinal cord compression at a cancer center: implications for palliative care services. (2000) (33)
- Tumour marker levels during marimastat therapy (1996) (32)
- Clinical presentation and long-term outcome of pure myoepithelial carcinoma of the breast. (2004) (32)
- DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy (2014) (32)
- Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo (2012) (32)
- Childhood T-cell lymphoblastic lymphoma--does early resolution of mediastinal mass predict for final outcome? The United Kingdom Children's Cancer Study Group (UKCCSG). (1995) (31)
- New drug development (2012) (31)
- Occult primary breast carcinoma presenting as axillary lymphadenopathy. (2002) (30)
- Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha. (1996) (30)
- Manually after-loaded 192Ir low-dose rate brachytherapy after subtotal excision and flap reconstruction of recurrent cervical lymphadenopathy from head and neck cancer. (2006) (30)
- Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? (2003) (30)
- Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer (2010) (29)
- Autonomic Nerve Trauma at Radical Hysterectomy: The Nerve Content and Subtypes Within the Superficial and Deep Uterosacral Ligaments (2008) (29)
- Outcome of treatment for limb and limb girdle sarcomas at the Royal Marsden Hospital. (2000) (29)
- Using an interactive video disk in breast cancer patient support. (1998) (29)
- Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skin. (2011) (28)
- Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems. (1989) (28)
- Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model. (2003) (27)
- Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039) (2014) (27)
- Platinum-Taxol non-cross resistance in epithelial ovarian cancer. (1995) (27)
- Association between polymorphisms of the GPX1 gene and second primary tumours after index squamous cell cancer of the head and neck. (2005) (26)
- Predicting the outcome of radical radiotherapy for invasive bladder cancer. (1993) (26)
- A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer (2004) (24)
- Intra‐abdominal metastases from soft tissue sarcoma (2004) (24)
- Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. (2006) (23)
- Clinical outcome and service implications of screening women at increased breast cancer risk from a family history. (2006) (23)
- Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. (2015) (23)
- Patient‐specific mutation databases for oral cancer (1999) (22)
- Non-surgical aspects of ovarian cancer Report of a Meeting of Physicians and Scientists, Institute of Cancer Research and the Royal Marsden Hospital, London (1994) (22)
- Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls. (1994) (22)
- Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck. (1997) (21)
- Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. (2000) (20)
- Identification of patients at low risk of dying after acute myocardial infarction, by simple clinical and submaximal exercise test criteria. (1988) (20)
- Evaluation of outcome after immediate breast reconstruction: prospective comparison of four methods. (2005) (20)
- Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy. (2010) (20)
- Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer. (2005) (19)
- Sweat-gland tumours: a clinical review of cases in one centre over 20 years. (2006) (19)
- GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma. (2000) (19)
- Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin (2012) (18)
- Who would have thought a single Ki67 measurement would predict long-term outcome? (2009) (18)
- Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer (2014) (18)
- Breast cancer, prostaglandins and patient survival. (1989) (17)
- Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast. (2001) (17)
- Multicentric breast cancer: clonality and prognostic studies (2011) (16)
- No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours (2001) (16)
- Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo (2010) (16)
- An audit of outcome of adjuvant post-operative radiotherapy for 52 women with stage II carcinoma of the endometrium. (2000) (16)
- Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. (2014) (15)
- Prostate-Specific Antigen in Nipple Aspiration Fluid: Menstrual Cycle Variability and Correlation with Serum Prostate-Specific Antigen (2002) (15)
- Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanoma (2007) (13)
- The Effects of Neoadjuvant Anastrozole and Tamoxifen on Circulating Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor 1 in Breast Cancer (2008) (13)
- A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma. (1996) (12)
- Sentinel-node biopsy in melanoma. (2007) (12)
- Le Fort I osteotomy and low-dose rate Ir192 brachytherapy for treatment of recurrent nasopharyngeal tumours. (2003) (12)
- Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer (1984) (11)
- The role of diagnostic CT scanning of the brachial plexus and axilla in the follow-up of patients with breast cancer. (1992) (11)
- Proposed 5-step World Health Organization analgesic and side effect ladder (2007) (10)
- Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders. (2009) (10)
- Non-Disseminated Breast Cancer: Controversial Issues in Management (1993) (10)
- Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia? (2002) (10)
- Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines (2008) (10)
- Primary malignant tumors of the iliopsoas compartment (2004) (10)
- A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. (2009) (10)
- Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer (2013) (10)
- Shared decision-making using an interactive video disk system for women with early breast cancer (1998) (9)
- Anti-&agr;Gal-dependent complement-mediated cytotoxicity in metastatic melanoma (2006) (9)
- Widening eligibility to phase II trials: constant arcsine difference phase II trials. (2004) (9)
- A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. (2010) (8)
- Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard Ratios. (2018) (8)
- Mammographic accuracy and patient age: a study of 297 patients undergoing breast biopsy. (1993) (8)
- The early diagnosis of breast cancer--a twenty-year experience at the Royal Marsden Hospital. (1992) (7)
- Results of a Phase III Multi-centre Randomised Controlled Trial of Intensity Modulated (IMRT) vs Conventional Radiotherapy (RT) in Head and Neck Cancer (PARSPORT: ISRCTN48243537; CRUK/03/005) (2010) (7)
- Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer (2014) (6)
- A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms. (2009) (6)
- Excision margins in high-risk malignant melanoma - Reply (2004) (6)
- Tamoxifen and endometrial lesions (1993) (6)
- Abstract P1-13-03: Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse. (2012) (6)
- Buttock Soft Tissue Sarcoma: Clinical Features, Treatment, and Prognosis (2003) (6)
- Statistical power: a measure of the quality of a study. (1995) (5)
- DUCT CARCINOMA-IN-SITU: CAN WE PREDICT RECURRENCE AFTER SURGERY? (1989) (5)
- Short-term presurgical treatment for all? (2007) (5)
- How does tamoxifen interact with chemotherapy? (1991) (5)
- Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. (2014) (5)
- Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma. (2015) (5)
- A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT). (2011) (4)
- Females with paired occurrence of cancers in the UADT and genital region have a higher frequency of either Glutathione S-transferase M1/T1 null genotype (2005) (4)
- 104P Phase II Randomized Study of Pre-Operative Pf-04691502 Plus Letrozole Compared with Letrozole (L) In Patients with Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer (Bc) (2012) (4)
- Prognostic (Px) significance of Ki67 before and after neoadjuvant chemotherapy (CT) in early breast cancer (2007) (4)
- More Breast Cancer Findings from the Women's Health Initiative (2003) (3)
- A more rational basis for determining the activities used for radionuclide imaging? (1997) (3)
- Radical hysterectomy for early stage cervical cancer and resulting morbidity. (2001) (3)
- Carcinoma within a Field of Cancerization Identify Patients at Risk of Developing Oral Squamous Cell A Case-Control Study Confirms That Microsatellite Assay Can (2000) (3)
- Phase II study of gemcitabine and docetaxel as first-line chemotherapy in locally advanced/metastatic leiomyosarcoma. (2009) (3)
- Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer (2002) (2)
- Lack of Correlation between Genetic Polymorphisms in Tamoxifen Metabolizing Enzymes with Primary Endpoints in the IMPACT Trial. (2009) (2)
- Good manners for the pharmaceutical industry (1997) (2)
- Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer. (2010) (2)
- Abstract PD07-07: Prediction of antiproliferative response to lapatinib by HER3 in an exploratory analysis of HER2-non-amplified (HER2−) breast cancer in the MAPLE presurgical study (CRUK E/06/039) (2012) (2)
- ER, PgR, c-erbB2 and EGFr in patients randomised to adjuvant tamoxifen or no treatment: associations with treatment benefit (1999) (2)
- Characterisation of TP 53 abnormalities in chronic lymphocytic leukaemia (2004) (2)
- Early Acquired Resistance to Endocrine Therapy: Extending the Neoadjuvant Model. (2009) (1)
- How Much of the Effect of Chemotherapy Is Due to Hormonal Manipulation (1993) (1)
- Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients. (2011) (1)
- TAMOXIFEN THERAPY, OESTROGEN RECEPTOR STATUS, AND POSTMENOPAUSAL BREAST CANCER (1985) (1)
- Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo (2012) (1)
- Abstract P6-06-03: Differing patterns of treatment effect in a trial assessing sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) (2013) (1)
- Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups (2011) (1)
- Employing multiple synchronous outcome samples per subject to improve study efficiency (2021) (1)
- OT2-03-04: A Trial Model for the Future in the Search for Personalised Medicine – The UK POETIC and EPHOS-B Perioperative Trials Experience. (2011) (1)
- The Cancer Research Campaign trials of adjuvant therapy for early breast cancer. (1989) (1)
- A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM). (2011) (1)
- A randomised phase II trial of pre-operative navelbine/epirubicin (NE) versus navelbine/mitozantrone (NM) versus adriamycin/cyclophosphamide (AC) for early breast cancer (2001) (1)
- 46. Understanding of prognosis on the psychological impact of recurrent breast cancer (1995) (1)
- Comparative Validation of the SP6 and MIB1 Antibodies to Ki67 and Their Use in Tissue Microarray (TMA) and Image Analysis for Breast Cancer. (2009) (1)
- A nerve-sparing radical hysterectomy: guidelines and feasibility in Western patients (2002) (1)
- OC-0392: Tumour characteristics associated with local relapse after hypofractionated radiotherapy in early breast cancer (2015) (1)
- DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy (2014) (0)
- Prediction of early death among patients (pts) enrolled in phase I trials: Development and validation of a new model based on platelet count and albumin level. (2012) (0)
- SP-0394: Cost-effectiveness of radiotherapy in Europe: a uniform solution for a heterogeneous context? (2010) (0)
- Abstract LB-222: Lapatinib has antiproliferative effects in both HER2 positive (+) and HER2 negative (-) breast cancer (BC): results from the MAPLE short-term pre-surgical trial (CRUK E/06/039) (2012) (0)
- 0-44. Are we using the right questionnaires when screening for anxiety and depression in women with early breast cancer? (1997) (0)
- Progesterone receptor levels are associated with time to aromatase inhibitor treatment failure in estrogen receptor-positive advanced breast cancer. (2009) (0)
- Need for Estradiol Assays With a Lower Functional Sensitivity in Clinical Studies Examining Postmenopausal Women Treated With Aromatase Inhibitors Reply (2013) (0)
- Artificial saliva versus pilocarpine for xerostomia (multiple letters) [1] (1999) (0)
- Gestational trophoblastic disease with liver metastases: the charing cross experience (1997) (0)
- THE SIGNIFICANCE OF TUMOUR CALCIFICATION IN OVARIAN CARCINOMA (2004) (0)
- P4-01-01: Preclinical and Clinical Studies of Estrogen Deprivation Support the PDGF/Abl Pathway as a Novel Therapeutic Target for Overcoming Resistance. (2011) (0)
- Quantitative estimates of the effects of concomitant chemotherapy on acute dysphagia in patients receiving radical treatment for head and neck cancer (2009) (0)
- Abstract P3-06-09: Test of association between Ki67 index of early breast cancer and local relapse after adjuvant hypofractionated radiotherapy. (2012) (0)
- Does immediate post mastectomy reconstruction delay adjuvant therapy (2001) (0)
- Personalized Medicine and Imaging Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer (2014) (0)
- Interferon α increases toxicity of cisplatin + 5-fluorouracil in patients with relapsed squamous cell carcinoma of the head and neck (1993) (0)
- A sequential doublet chemotherapy regimen in patients (pts) with advanced endometrial adenocarcinoma (EC) and gynecological mixed müllerian tumors (MMT). Maintaining activity with tolerability (2005) (0)
- Abstract P6-07-15: The effect of taxanes in ER+ early breast cancer is likely to be mitigated by chromosomal instability. (2012) (0)
- Leukopenia predicts outcome in haemato-oncological patients requiring intensive care (2001) (0)
- PO-0915: High p53 levels after a radiotherapy dose, but not residual DNA DSBs, are associated with late normal tissue reactions (2013) (0)
- Synovial sarcoma: experience of 150 cases in 11 years (1999) (0)
- Book reviewsNonparametric Receiver Operating Characteristic Analysis (Version 2.5). Computer Program. By VidaS, 1995 (S Vida, Montreal General Hospital, Quebec), Canadian $60.00. (1995) (0)
- Quantitative estimates of the effects of concomitant chemotherapy on acute dysphagia in patients receiving radical treatment for head and neck cancer. (2009) (0)
- The impact of radiotherapy on the outcome of immediate post-mastectomy breast reconstruction using implants, with and without myocutaneous flap transfer (2001) (0)
- National Randomised Trial of Hormone Replacement Therapy in Women with a History of Early Stage Breast Cancer (2001) (0)
- Phase I feasibility study of carboplatin plus capecitabine followed by maintenance capecitabine in patients (pts) with recurrent platinum-sensitive epithelial ovarian cancer (EOC). (2016) (0)
- Upper limb pain and functional morbidity following breast cancer treatment - A cross sectional survey (2023) (0)
- Perioperative therapy in HER2+ patients (2009) (0)
- Symposium on methodology and quality assurance in cancer clinical trials: Cancer treatment reports, number 10, 1039–1233 (1987) (0)
- A Case-Control Study Confirms That Microsatellite Assay Can Identify Patients at Risk of Developing Oral Squamous Cell Carcinoma within a Field of Cancerization 1 (2000) (0)
- The role of computed tomography in the assessment of response to limb compression in unilateral lymphoedema (1993) (0)
- Radiation-induced Gene Expression and Differentiation Status of Fibroblast Cultures from Breast Cancer Patients with and without Late Reaction to Radiotherapy (2010) (0)
- S6-6: Expression of Key Estrogen-Regulated Genes (ERGs) Differ Substantially across the Menstrual Cycle in ER+ Breast Tumours. (2011) (0)
- EFFECTS OF TAMOXIFEN ON UTERUS. AUTHORS' REPLY (1994) (0)
- Headandnecksarcomas:prognostic factors andimplications for treatment (1993) (0)
- Clinical Cancer esearch cer Therapy : Preclinical logical Evidence for Dual Antiangiogenic-Antiaromatase R ivity of the VEGFR Inhibitor PTK 787 / ZK 222584 In vivo (2010) (0)
- 553 POSTER Stem cell mobilisation by hyperbaric oxygen (HBO) (2007) (0)
- Diagnostic Cytopathology (1994) (0)
- The importance of (A) rapid data processing and (B) randomization in phase II trials of cytotoxics in oncology illustrated by the trials of an analogue of cisplatin (1984) (0)
- MONITORING RARE EVENTS IN A SINGLE ARM NON-INFERIORITY TRIAL (111; CRUK/09/011) (vol 9, pg 539, 2012) (2014) (0)
- 26PGENE EXPRESSION OF ESR1, PGR AND HER2 IN LYMPH NODE HOMOGENATES AND CONCORDANCE WITH IHC IN PRIMARY BREAST TUMOURS (2014) (0)
- Abstract 4029: The impact of multiple drug resistance mechanisms on microarray predictive gene signature performance. (2013) (0)
- Meta-analysis of cancer trials: a new approach to the assessment of treatment. (1987) (0)
- Integration of Ki67 with residual cancer burden (RCB) compared to Ki67 or RCB alone to predict long-term term outcome following neoadjuvant chemotherapy. (2013) (0)
- Ductcarcinoma insitu: predictors oflocal recurrenceandprogression in patients treated bysurgeryalone (1990) (0)
- TUMOUR MARKER LEVELS DURING MARIMASTAT THERAPY. AUTHORS' REPLY (1996) (0)
- Abstract P1-08-03: Prediction of response to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer by IHC4 or Ki67 alone (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Roger P. A’hern?
Roger P. A’hern is affiliated with the following schools:
